Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors
April 20 2020 - 04:05PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced the appointment of Scott Whitcup, M.D. to
the Company’s Board of Directors.
“We are delighted to welcome Scott to our board,” said
Patrick Machado, J.D., Board Chair of Adverum Biotechnologies.
“Scott's expertise and accomplished track record as an
ophthalmologist and successful drug developer fit perfectly with
Adverum's mission to substantially elevate the standard of clinical
care for patients suffering from neovascular AMD and other
vision-threatening indications. My colleagues and I all look
forward to working with Scott to realize fully the significant
potential benefits our technology offers patients at risk of losing
their sight.”
“This is an exciting time to join Adverum’s Board as the company
strategically executes on expanding its pipeline through its novel
vector discovery and drug development expertise to commercialize
gene therapies to treat patients with serious ocular and rare
diseases,” said Dr. Whitcup. “The development progress of ADVM-022,
including the promising clinical data demonstrated to date in the
OPTIC trial, has been impressive. I look forward to partnering with
the Board, and the Adverum management team, on further developing
the pipeline of drug candidates and advancing ADVM-022 towards
commercialization for patients with wet AMD and diabetic
retinopathy.”
Scott Whitcup, M.D. is the founder and chief executive officer
of Akrivista and Whitecap Biosciences, two companies focused on
developing new therapies in ophthalmology and dermatology. In
addition, he is on the clinical faculty at the UCLA Stein Eye
Institute. Previously, Dr. Whitcup was the executive vice president
of research and development and chief scientific officer at
Allergan, where he led the discovery, clinical development, and
medical affairs organizations focused on therapeutic areas
including ophthalmology, CNS, urology, dermatology, and medical
aesthetics. Earlier at Allergan, he served as vice president and
head, ophthalmology therapeutic area, where he secured regulatory
approvals for Alphagan P®, Lumigan®, Restasis®, and Ozurdex®.
Earlier in his career, Dr. Whitcup was the clinical director at the
National Eye Institute at the National Institutes of Health (NIH).
Dr. Whitcup earned a B.A. from Cornell University and an M.D. from
Cornell University Medical College. He completed an internal
medicine residency at UCLA and an ophthalmology residency at
Harvard University at the Massachusetts Eye and Ear
Infirmary.
Dr. Whitcup serves on the board of directors of Scilex
Pharmaceuticals and Anivive Lifesciences.
About Adverum BiotechnologiesAdverum
Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy
company targeting unmet medical needs in serious ocular and rare
diseases. Adverum is evaluating its novel gene therapy candidate,
ADVM-022, as a one-time, intravitreal injection for the treatment
of its lead indication, wet age-related macular degeneration. For
more information, please visit www.adverum.com.
Investor and Media Inquiries:Investors:Myesha
LacyAdverum Biotechnologies,
Inc.mlacy@adverum.com1-650-304-3892
Media:Cherilyn Cecchini, M.D.LifeSci
Communicationsccecchini@lifescicomms.com 1-646-876-5196
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2023 to Mar 2024